Application of novel exact combinatorial optimisation techniques and metaheuristic methods for problems in cancer research. Novel biotechnologies are offering an unprecedented opportunity to understand the genetic basis of cancer development and progression. However, they present us with a challenge; new computational methods and improved mathematical models and algorithms need to be introduced to complement these technologies in the determination of the function of our individual genetic makeup ....Application of novel exact combinatorial optimisation techniques and metaheuristic methods for problems in cancer research. Novel biotechnologies are offering an unprecedented opportunity to understand the genetic basis of cancer development and progression. However, they present us with a challenge; new computational methods and improved mathematical models and algorithms need to be introduced to complement these technologies in the determination of the function of our individual genetic makeup, especially in connection with disease states. The project will deal with research questions and datasets related to some of the highest incidence cancers in Australia. This project will contribute towards the development of new powerful algorithms for pattern recognition for future "personalized" molecular diagnostics methods.Read moreRead less
Molecular response to interferon beta treatment in multiple sclerosis. Inteferon beta (IFNb) is the frontline drug for treatment of multiple sclerosis. However, in many patients this expensive drug provides no benefit, resulting in unnecessary, uncontrolled disease progression, and in a waste of many millions of dollars each year. A common explanation for this treatment failure is the development of neutralising antibodies (NABs). We will establish the prevalence and effects of NABs in Austra ....Molecular response to interferon beta treatment in multiple sclerosis. Inteferon beta (IFNb) is the frontline drug for treatment of multiple sclerosis. However, in many patients this expensive drug provides no benefit, resulting in unnecessary, uncontrolled disease progression, and in a waste of many millions of dollars each year. A common explanation for this treatment failure is the development of neutralising antibodies (NABs). We will establish the prevalence and effects of NABs in Australian patients, use novel techniques to identify biomarkers for IFNb response, evaluate the diagnostic and therapeutic value of the biomarkers, and develop a new test for NABs. Tailored use of this drug, and possible new therapeutic targets, will result, benefiting the patient and community.Read moreRead less